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Available online 10 October 2014Thrombosis is a common pathology underlying ischemic heart disease, ischemic stroke, and venous thromboem-
bolism (VTE). The Global Burden of Disease Study 2010 (GBD 2010) documented that ischemic heart disease and
stroke collectively caused one in four deaths worldwide. GBD 2010 did not report data for VTE as a cause of death
and disability.We performed a systematic reviewof the literature on the global disease burdendue to VTE in low,
middle and high income countries. Studies from Western Europe, North America, Australia, and Southern Latin
America (Argentina) yielded consistent results with annual incidences ranging from 0.75 to 2.69 per 1,000 indi-
viduals in the population. The incidence increased to between 2 and 7 per 1,000 among those 70 years of age or
more. Although the incidence is lower in individuals of Chinese and Korean ethnicity, their disease burden is not
low because of population aging. VTE associated with hospitalization was the leading cause of disability-
adjusted-life-years (DALYs) lost in low and middle income countries, and second in high income countries,
responsible for more DALYs lost than nosocomial pneumonia, catheter-related blood stream infections, and
adverse drug events. VTE causes a major burden of disease across low, middle, and high income countries.
More detailed data on the global burden of VTE should be obtained to inform policy and resource allocation in
health systems, and to evaluate if improved utilization of preventive measures will reduce the burden.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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A doubling of life expectancy and quadrupling of the world pop-
ulation during the 20th century have been associated with a transi-
tion from infectious to non-communicable diseases as the major
cause of death and disability worldwide [1–3]. Cardiovascular dis-
ease is a leading contributor to the burden caused by non-
communicable diseases. Thrombosis is themost common underlying
pathology of the three major cardiovascular disorders: ischemic
heart disease (acute coronary syndrome), stroke, and venous throm-
boembolism (VTE).
The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD
Study), which was initiated by the World Health Organization and the
World Bank, is a systematic scientiﬁc investigation aimed at quantifying
the comparative magnitude of health loss due to diseases, injuries and
risk factors by age, sex and geographic region throughout the world
[3–5]. The most recent version of this effort, GBD 2010, documents the
number of deaths from 235 causes from 1990 through 2010, using
data from 187 countries and 21 regions; these regions are grouped fur-
ther into 7 super-regions [4,5]. The study also provides estimates of the
years of life lost due to premature mortality (YLL), the years lived with
disability (YLD) and the disability-adjusted life years (DALYs) [4,5].
DALYs estimate how many years of healthy life are lost because of
premature death or non-fatal illness or disability, and are calculated as
the sum of YLL and YLD [6].
GBD 2010 documented 52.8 million deaths globally in 2010 [3].
Non-communicable disease accounted for 34.5 million deaths, or two
out of every three deaths [3]. Ischemic heart disease (7.0 million
deaths) and stroke (5.9 million deaths) collectively caused one in four
deaths worldwide [3]. The 7.0 million deaths from ischemic heart dis-
ease represent a 35% increase since 1990. About half of all stroke deaths
were from ischemic stroke, which is caused by thrombosis. The 2.8 mil-
lion deaths from ischemic stroke represent a 25% increase since 1990.
Although there is substantial regional variation, ischemic heart disease
ranks as the number one or two causes of YLL in 13 of the 21 regions,
and ranks in the top ﬁve causes of death in 17 regions [3]. Stroke
ranks as the ﬁrst or second cause of YLL in 8 regions, and is in the top
ﬁve causes in 14 regions [3]. Ischemic heart disease was the leading
cause of DALYs lost worldwide in 2010 (up from fourth rank in 1990,
an increase of 29%), and stroke was the third leading cause (up from
ﬁfth rank in 1990, an increase of 19%) [6].More than 60% of new strokes,
and 45% of deaths from stroke occur in individuals less than 75 years of
age [7].
GBD 2010 clearly documents the major impact of arterial
thrombosis on global disease burden because it is the pathological
mechanism underlying most cases of ischemic heart disease and is-
chemic stroke. However, the study does not report data for VTE as a
speciﬁc cause of death and disability. A cursory review of the liter-
ature fromWestern Europe and North America suggests that VTE is
a major contributor to the burden from non-communicable dis-
eases. For example, Cohen and colleagues used an incidence-
based epidemiology model to estimate the number of non-fatal
symptomatic VTE events, which includes both deep-vein thrombosis
(DVT) and pulmonary embolism (PE), and the number of VTE - related
deaths across the European Union in 2004 (population 454.4 million)
[8]. The results yielded estimates of 684,019 DVT events; 434,723 PE
events; and a total of 543,454 VTE - related deaths [8]. In the United
States, investigators from the Centers for Disease Control and Preventionused data from the National Hospital Discharge Survey to estimate there
were an average of 547,596 adult hospitalizations with a diagnosis of
VTE each year during 2007 to 2009 among the population of 301 to
307 million [9]. If VTE causes a proportionate burden of disease across
the other global regions, it would be highly ranked in the causes of
death and DALYsworldwide. Given thatmuch of themortality andmor-
bidity from VTE is potentially preventable [10–13], data on the disease
burden are important for health systems and policymakers for planning
resource allocation, both for health care delivery and for setting research
priorities.
We therefore performed a systematic review of the literature on the
global burden of disease due to VTE. The objective was to review the
evidence for disease burden in each of the geographic regions speciﬁed
in the GBD Study 2010, using the variables of annual incidence rate
(number of new cases each year per 1,000 population at risk), prevalence
(proportion of the population with the condition at a point in time),
annual number of deaths, and DALYs.Methods
Literature Search and Review
A computer search of the literature was performed using OVID
Medline, OVID Medline In-Process and Other Non-Indexed Citations,
and EMBASE, from inception of these databases to May 2014. We used
the disease-related key words venous thromboembolism, deep-vein
thrombosis, venous thrombosis, vein thrombosis, thrombophlebitis,
pulmonary embolism, and lung embolism, together with the additional
key words incidence, prevalence, mortality, case fatality, morbidity,
surveillance and epidemiology, years lived with disability (YLD), and
disability –adjusted life years (DALY), to search the titles and abstracts
of articles in these databases. We also reviewed the bibliographies of
published articles. We excluded non-human studies, case reports and
clinical trials, as well as non-relevant publication types, including re-
ports of clinical conferences and editorials. We also excluded articles
published in languages other than English; and the current report is
conﬁned to the literature published in English. The identiﬁed citations
from each database were exported to an ENDNOTE library where the
citations were de-duplicated. The merged list of citations was exported
to aWord document that included citation number, title, list of authors,
the full abstract, and the journal citation.
The abstractswere reviewed independently by two reviewers (A.W.,
G.R) who categorized them according to the level of evidence as either
level A, level B, or other; disagreements were resolved through discus-
sion and consensus. Level A evidence was deﬁned as population-based
estimates of the parameters of the disease burden (incidence, preva-
lence, number of deaths, DALYs) in the general population (age
18 years or older) derived from either population-based cohort studies,
or from analysis of national health system databases or private health
insurance claims data within a deﬁned population, or derived using a
combination of the former methods with appropriate epidemiologic
modeling methods. Level B evidence was deﬁned as estimates of the
burden in speciﬁc sub-populations such as the elderly, pregnancy, etc.
using the same methods described for level A. The category of “Other”
evidence included all other study designs without a deﬁned population
to derive the disease burdenparameters, such as single hospital base co-
hort studies or record review, and autopsy studies. Population-based
mortality studies based on hospital discharge or other databases, or
Table 1
Studies comprising Level A evidence for burden of disease from Venous Thromboembolism (VTE): incidence per 1,000 population per year.
Author and Year Study Design Global Super Region Global Region Country VTE Incidence DVT Incidence PE Incidence
Hald et al. 2013 [14] Population-based cohort combined with hospital based discharge diagnosis,
autopsy and procedure registries
High Income Western Europe Norway 1.48 NR NR
Holst et al. 2010 [15] Population-based cohort combined with national cause of death registry
and national patient registry
High Income Western Europe Denmark 2.69 NR NR
Moretti et al. 2010 [16] Population -based hospital discharge database High Income Western Europe Italy NR NR 0.189
Severinsen et al. 2010 [17] Population based cohort in men and women age 50 to 64 combined with
the National patient registry
High Income Western Europe Denmark 1.15 0.65 0.51
Cohen et al. 2007 [8] Incidence -based epidemiologic model of country-speciﬁc non-fatal VTE
events and VTE -related deaths
High Income Western Europe France, Germany,
Italy, Spain,
Sweden, UK
NR 1.48 0.95
Heurta et al. 2007 [18] Prospective population -based cohort identiﬁed using the General Practice
database. Nested case-control analysis also done
High income Western Europe UK 0.745 0.403 0.342
Naess et al. 2007 [19] Population-based cohort identiﬁed by electronic hospital registries and
case-ﬁnding search of tertiary care center for discharge diagnoses of VTE
High Income Western Europe Norway 1.43 0.93 0.50
Guijarro et al. 2005 [20] Hospital discharge database of the Andalusian health care service for 1998 to 2001 High Income Western Europe Spain 0.036⁎ NR 0.15⁎
Oger et al. 2000 [21] Population -based cohort study of both hospitalized and outpatient cases
within a deﬁned populations in 1998 and 1999 using standardized
prospective data collection
High Income Western Europe France 1.83 1.24 0.60
Nordstrom et al. 1992 [22] Population-based cohort of hospital based venography cases in 1987 High Income Western Europe Sweden NR 1.55 male
1.62 female
NR
Kierkegarrd 1980 [23] Population-based cohort of hospital based venography cases High Income Western Europe Sweden NR 0.85 male
0.68 female
NR
Tagalakis et al. 2013 [24] Provincial healthcare databases linking hospital discharges and healthcare
claims data 2000 through 2009
High Income North America Canada
(Quebec)
1.22 0.78 0.45
Yusuf et al. 2012 [9] Search of the National Hospital Discharge database 2007 - 2009 High Income North America USA 2.39 1.52 1.15
Weiner et al. 2011 [25] HCUP Nationwide inpatient sample of hospital discharges and national
cause of death ﬁle databases 1998- 2006
High Income North America USA NR NR 1.12
Cushman et al 2004 [26] Population-based cohort with prospective follow-up of patients combined
with search of hospital discharge and Medicare records
High Income North America USA 1.61 1.17 0.45
Stein et al. 2004 [27] Search of the National Hospital Discharge database High Income North America USA 1.30⁎⁎ 1.04⁎⁎ 0.36⁎⁎
Janke et al. 2000 [28] Vital statistics data obtained from the Minnesota State Department of Health
and hospital discharge data from a State uniform billing claims database 1980 to 1994
High Income North America USA NR NR 0.60 to 0.90 male
0.60 female
Klatsky et al. 2000 [29] Population-based cohort of a California pre-paid health plan for 1978
through 1985 combined with hospital record review
High Income North America USA 0.19⁎⁎⁎ NR NR
Silverstein et al. 1998 [30] Population-based cohort with medical record review and search of
computerized databases of diagnoses and procedures, billing data, death
certiﬁcates and autopsy records
High Income North America USA 1.17 0.48 0.69
White et al. 1998 [31] Database analysis of the linked California patient discharge data set High Income North America USA NR 0.230⁎⁎⁎⁎ NR
Anderson et al. 1991 [32] Population-based cohort of hospital cases with hospital record review High Income North America USA 1.07 0.48 0.23
Shiraev et al. 2013 [33] National databases on hospitalization and deaths 2009 to 2010 High Income Australasia Australia NR NR 0.53
Ho et al. 2008[34] Population-based cohort study with cases identiﬁed prospectively and also
retrospectively through Western Australian Department of Health database
High Income Australasia Australia 0.83 0.52 0.31
Vazquez et al. 2013 [35] Population-based cohort within a health maintenance organization High Income Southern Latin
America
Argentina 1.65 1.30 0.64
Jang et al. 2010 [36] National Health Insurance database in 2008 High Income High Income
Asia Paciﬁc
Korea 0.138 0.0531 0.0701
Lee et al 2010 [37] National health Insurance claims database for Taiwan Southeast Asia,
East Asia, Oceania
East Asia Taiwan 0.159 NR NR
Cheuk et al. 2004 [38] Database of Hong Kong Hospital Authority of all hospitalizations, diagnoses,
procedures and outcomes 2000 to 2001
Southeast Asia,
East Asia, Oceania
East Asia Hong Kong NR 0.171 0.039
Woo et al. 1988 [39] National vital statistics analysis combined with hospital record review
(rate is for 1985)
Southeast Asia,
East Asia, Oceania
East Asia Hong Kong 0.079 NR NR
⁎ This study evaluated cases where VTE or PE was the primary reason for hospital admission.
⁎⁎ The rates are for the Caucasian population. Corresponding incidence rates for African Americans were VTE 1.38, DVT 107, PE 0.40, and for Asian/Paciﬁc Islanders were VTE 0.26, DVT 0.22, and PE 0.07.
⁎⁎⁎ The rate is for overall population. Corresponding incidence rates by race were Caucasian 0.21, African American 0.22, Asian 0.02, and Hispanic 0.09.
⁎⁎⁎⁎ The rate is for a ﬁrst idiopathic DVT in Caucasian population. Corresponding incidence rates by race were African American 0,293, Hispanic 0.139, and Asian/Paciﬁc Islander 0.060.
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egory of “Other.” This article focuses on the Level A evidence for overall
disease burden according to global region. Selected Level B evidence on
the relationship between age and disease burden were also included
where relevant. The evidence categorized as “Other”was not systemat-
ically reviewed.
To simplify comparison of incidence results across studies and
between global regions, all incidence rates were converted to a rate
per 1,000 individuals per year.
Results
Literature Search
The computerized literature search identiﬁed a total of 9,603 cita-
tions. Of these citations, 8,817 (92%) were in the English language.
After the de-duplication check, a total of 8,702 citations remained for
review.
The two independent reviewers were in agreement on the classiﬁed
level of evidence for 8,671 (99 %) of the 8,702 reviewed citations; the
remaining 31 citations were classiﬁed after discussion and consensus
between the reviewers. The ﬁnal classiﬁcation designated 29 citations
as level A evidence [14–42], 29 as level B evidence [43–71], and the
remainder as other. Most of the level A studies evaluated the incidence
of VTE or its components, DVT and/or PE [14–40]; two studies evaluated
the prevalence of VTE [41,42].
Incidence of VTE
The results of the studies classiﬁed as level A evidence of incidence
are summarized in Table 1.
This evidence comes from only two of the 7 global super regions des-
ignated by GBD 2010; those designated “High Income”, and “Southeast
Asia, East Asia, and Oceania”. Within the High Income super region, 11
level A studies were from the region of Western Europe [8,14–23],
10 were from North America, 2 were from Australasia (both from
Australia) [33,34], one was from the Southern Latin America region
(Argentina) [35], and one was from the Asia Paciﬁc region (Korea)
[36]. The three level A studies from the super region of “Southeast
Asia, East Asia, and Oceania” all came from the region of East Asia
[37–39] (two studies from Hong Kong and one from Taiwan).Table 2
Incidence rates per 1,000 population per year according to age category: studies comprising le
Author and Year Global Region Country A
Kroger et al. 2010 [40] Western Europe Germany 0
0
Naess et al. 2007 [19] Western Europe Norway 0
0
Oger et al. 2000 [21] Western Europe France 1
1
Nordstrom et al. 1992 [22] Western Europe Sweden 0
0
Tagalakis et al. 2013 [24] North America Canada (Quebec) 0
Yusuf et al. 2012 [9] North America USA 1
Silverstein et al. 1998 [30] North America USA 0
0
Anderson et al. 1991 [32] North America USA 0
Lee et al. 2010 [37] East Asia Taiwan N
Cheuk et al. 2004 [38] East Asia Hong Kong 0
Vazquez et al. 2013 [35] Southern Latin America Argentina (2006 -2012) N
Jang et al. 2011 [36] High Income Asia Paciﬁc Korea (2008) 0
0
Footnotes NR = Not reported.
* Age categories shown are 30 to 49, 50 to 69, and 70 to 90, ** Incidences are for DVT (all VTE
∞ Age categories shown are 40 to 59, 60 to 74, and 75 or more.
^ Age categories shown are 40 to 44, 50 to 54, 60 to 64, 70 to 74, and 80 to 84, ^^ Age categor
⁎⁎⁎ Rates are shown in graphical form; actual numerical values not provided.The relationship between increasing age and the incidence of VTE
was evaluated in several of the level A studies [9,19,21,22,24,30,32,
35–38,40]. The results of these studies are summarized in Table 2.
The level B studies evaluated the incidence of VTE in various sub-
populations, such as during pregnancy or the post-partum period
[43–54], males or females of selected age categories [55–64], sub-
groups with or without selected risk factors or comorbidities [65–70],
or special categories of thrombosis [71]. All but one of the level B studies
came from the super region designatedHigh Income; the exceptionwas
from Sub-Saharan Africa (South Africa) [51]. Within the High Income
super region, 14 of the level B studies were from the region of Western
Europe [43,44,46,49,54,55,57–59,61–63,65,69], 11 were from North
America [45,47,50,52,56,60,64,67,68,70,71], two were from Australasia
(both from Australia) [48,53], and one was from the high income Asia
Paciﬁc region (Japan) [66].
Prevalence of VTE
Two studies were identiﬁed that evaluated the prevalence of VTE;
both were done in the United States by the same investigators [41,42].
The national prevalence of VTEwas determined during the ﬁve year pe-
riod from 2002 through 2006 using a health insurance claims database
of 12.7 million enrollees that included both private insurance claims
andMedicare claims. The prevalence of VTEwas 3.2 per 1,000 enrollees
in 2002, and 4.2 per 1,000 enrollees in 2006 [41]. Among patients
65 years of age or older, the prevalence in 2006 was 13.8 per 1,000
enrollees, compared with 2.3 per 1,000 enrollees in those less than
65 years of age [41]. The authors used the 2006 data to project the US
national prevalence as 0.95 million cases, and to project the future prev-
alence in 2050 to be 1.82 million cases [41]. The second study found that
the prevalence of VTEwas highest in African - Americanmales, followed
by Caucasian males, Caucasian females, and African –American females
[42]. Hispanic individuals of both sexes had lower prevalence [42].
Disability Adjusted Life Years (DALYs)
Our search identiﬁed two studies that evaluated disease burden in
terms of DALYs [72,73]. The methodologically strongest was the study
by Jha and colleagues, as part of theWorldHealth Organization’s Patient
Safety Program [72]. This study used analytic modeling to estimate the
incidence rates of VTE, annual number of cases, and DALYs from VTEvel A evidence.
ge 40 to 49 Age 50 to 59 Age 60 to 69 Age 70 to 79 Age 80 or more
.30 male*
.28 female
------- 1.24 male
0.94 female
------- 3.45 male
3.72 female
.20 male^, **
.17 female
0.72 male
0.72 female
1.14 male
0.93 female
1.85 male
1.45 female
3.73 male
3.84 female
.52 male ∞
.05 female
--------- 5.33 male
4.53 female
------- 10.81 male
12.04 female
.69 male **
.97 female
2.85 male
1.03 female
3.27 male
2.17 female
5.64 male
4.29 female
7.65 male
8.22 female
.83 1.42 2.57 4.41 6.85
.43 2.00 3.91 7.27 11.34
.90 male^
.45 female^
0.76 male
0.83 female
1.63 male
1.69 female
6.46 male
3.22 female
9.84 male
8.49 female
.17 ** 0.43 1.19 2.32 2.91
R⁎⁎⁎ NR⁎⁎⁎ NR⁎⁎⁎ NR⁎⁎⁎ 8.31 male
11.82 female
.096^^ ------- -------- 0.81^^
R⁎⁎⁎ NR⁎⁎⁎ NR⁎⁎⁎ NR⁎⁎⁎ 5.93
.099 male
.097 female
0.173 male
0.131 female
0.381 male
0.412 female
0.765 male
1.042 female
1.088 male
1.092 female
not reported).
ies shown are 45 to 64, and 65 or more.
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tries [72]. The data for the modeling were generated from two sources;
an extensive literature review, and epidemiologic studies commis-
sioned by the WHO, which were conducted in 26 hospitals across
eight low and middle income countries in the Eastern Mediterranean
and North Africa regions (Egypt, Jordan, Kenya, Morocco, South Africa,
Sudan, Tunisia, Yemen) [74], and in 35 hospitals across ﬁve countries
in Latin America (Argentina, Colombia, Costa Rica, Mexico, and Peru)
[75]. This approach enabled the authors to estimate the number of
VTE events associated with hospitalization during 2009 for 117.8 mil-
lion hospitalizations among 1.1 billion citizens of high income coun-
tries, and for 203.1 million hospitalizations among 5.5 billion citizens
of low and middle income countries [72,74,75].
The study reported incidences of VTE per 100 hospitalizations of 3.3
(95% conﬁdence interval [CI] 1.9 to 4.8) in high income countries, and
3.0 (95% CI 1.0 to 4.8) in low andmiddle income countries [72]. The es-
timated annual number of cases of VTE was 3.9 million (95% CI 1.9 to
6.3) for the high income countries, and 6.0 million (95% CI 1.2 to 12.8)
for the low and middle income countries. VTE was the leading cause
of hospital-related DALYs lost overall, being responsible for a full one-
third (7,681) of the total of 22,644 DALYs, and VTE accounted for
more DALYs lost than nosocomial pneumonia, catheter-related blood
stream infections, and adverse drug events [72]. VTE was the leading
cause of DALYs lost in the low andmiddle income countries, and ranked
second in the high income countries [72]. Premature death was the
source of 64% of the DALYs lost in high income countries and for 66%
of the DALYs lost in low and middle income countries [72].
The second study was conducted by the Australia and New Zealand
Working Party on the Management and Prevention of Venous Throm-
boembolism [73]. This group used incidence data from Western
Australia, together with mortality estimates and disability weighting
derived from the literature, much of which comes from other countries,
to estimate the DALYs associated with VTE in Australia for the year
2008. The estimated overall loss for Australia in 2008 was 78,408
DALYs [73]. The premature mortality (YLL) was 99.7% of the estimated
total burden of disease [73].
Discussion
The results of our systematic review of the literature suggest several
inferences. First, there is substantial evidence that VTE is associated
with a major global burden of disease. Second, most of the level A
evidence of this burden comes from the super region “High Income”
deﬁned by GBD 2010, although some evidence also comes from the
super region of “Southeast Asia, East Asia and Oceania” (Table 1).
Third, the evidence of disease burden is primarily based on the inci-
dence of VTE events, and to a lesser extent on the estimated number
of deaths for a region or country. Our review identiﬁed only one rigor-
ous study estimating the DALYs associated with VTE [72]. Fourth,
there is consistent and strong evidence that the global incidence of
VTE increases with increasing age, and is especially pronounced in the
elderly (Table 2). This ﬁnding has major implications for global health
because life expectancy continues to improve in low andmiddle income
countries, and these countries continue the transition from infectious
diseases to non-communicable diseases as the major cause of death
and disability. Finally, the evidence and the above inferences lead us
to recommend that VTE be measured as a speciﬁc cause of death in
future efforts of the GBD project. We expand further on these themes
in the paragraphs below.
Regarding the annual incidence of VTE, the studies from Western
Europe, North America, Australia, and Southern Latin America
(Argentina) yielded consistent ﬁndings. These studies reported overall
annual incidences ranging from 0.75 to 2.69 per 1,000 individuals in
the population, with the incidence in most of the studies ranging
between 1.07 and 1.83 (Table 1). The study by Oger and colleagues
[21] reported that the incidence of VTEwas similar to that ofmyocardialinfarction in the same country during a similar time frame. Further, the
study by Jha and colleagues [72] estimated 3.9 million cases of hospital-
associated VTE during one year among 1.1 billion citizens of high
income countries (3.5 per 1,000 population), and 6.0 million cases
among 5.5 billion citizens of low and middle income countries (1.1 per
1,000 population) [72]. Thus, the aggregate evidence from the literature
indicates that VTE is a common condition globally across the spectrum
of high, middle and low income regions.
There was a strong and consistent association of increasing
incidence of VTE with increasing age. The annual incidence increased
to between 2 and 7 per 1,000 population among those 70 years of age
or more in most of the studies, and to between 3 and 12 per 1,000 pop-
ulation among those 80 years of age or older (Table 2). This ﬁnding has
major implications for healthcare systems and for the care of the elderly.
For example, a study of the incidence of VTE among nursing home res-
idents in Kansas reported an incidence of 13 per 1,000 residents per year
[70]. Reardon and colleagues analyzed nursing home records from 19
states in the United States, and found that 1 in 25 admissions had a
diagnosis of VTE [56]. It is likely that the high incidence of VTE in the
elderly reﬂects the high prevalence of co-morbid acquired risk factors
in these patients, especially malignancy, heart failure, and immobility
associated with surgery or hospitalization for medical illness, which ac-
count for themajority of the population attributable risk of VTE in older
individuals. In contrast, genetic factors account for only 7 to 22 per cent
of the population attributable risk in the elderly [76].
The signiﬁcant burden of VTE is not conﬁned to the elderly, and VTE
should not be considered a disease of old age. The annual incidence
among individuals in their 40s, 50s, and 60s ranged from 0.2 to 5.3 per
1,000 population (Table 2), with the incidence in the very contempo-
rary studies ranging from 0.8 to 3.9 [9,24].
The level A studies from Taiwan, Hong Kong, and Korea reported
lower annual incidences of VTE or DVT (ranging from 0.079 to 0.171
per 1000 population, Table 1 [37–39]). These results are consistent
with the ﬁndings of studies in the United States, which reported lower
annual incidences of VTE in Asian- Americans than in Caucasians and
African Americans [31]. There was also a strong association between in-
creasing age and increased incidence in the studies from Hong Kong,
Taiwan, and Korea [36–38] (Table 2). So, although the overall incidence
is lower in individuals of Chinese and Korean ethnicity, their disease
burden is not low because of population aging and increased life expec-
tancy. Recent studies undertaken in Asian countries have demonstrated
rates of VTE after major surgery and in hospitalized medical patients
approaching those observed in Western populations [77].
The literature review identiﬁed limited information on the number
of deaths due to VTE. The strongest evidence comes from the study by
Cohen and colleagues, who used an incidence-based model in six
European countries to estimate that there were 534,454 deaths related
to VTE across the European Union in 2004 [8]. A similar approach ap-
plied to the data from the United States suggested approximately
300,000 deaths from VTE each year [78,79]. The direct ascertainment
of deaths due to VTE is difﬁcult because of the low rate of autopsy in
most countries, and because autopsy studies have consistently demon-
strated that pulmonary embolism is often not diagnosed ante-mortem
and that deaths due to pulmonary embolism are frequently mis-
classiﬁed as cardiac deaths. Further, pulmonary embolism may be the
primary cause of death, such as in patients with unprovoked VTE, or a
secondary (contributing) cause of death, for example, in the cancer pa-
tient or the patient with multiple medical conditions. Secondary causes
may not always be documented or measured in studies of causes of
death. For these reasons, estimates of the number of deaths from VTE
based on death certiﬁcates or hospital discharge data will underesti-
mate the death burden.
Our review found limited information on the DALYs associated with
VTE. The study by Jha and colleagues [72] provides evidence that VTE
causes a major burden of disease across low, middle, and high income
countries. VTE was the highest ranked cause of DALYs overall among
936 G.E. Raskob et al. / Thrombosis Research 134 (2014) 931–938the seven causes of hospital-associated adverse events. However, because
the study only evaluated DALYs related to inpatient adverse events, it
underestimates the total contribution of VTE, since a substantial propor-
tion of VTE events occur out of hospital [78]. Premature death accounts
for approximately two-thirds of the DALYs lost due to VTE [72]. Thus,
even in patients with underlying chronic or terminal illness (eg. ad-
vanced heart failure or cancer), VTE causes earlier death for many of
these patients.
Disability was responsible for 34% of the DALYs associated with VTE
[72], indicating that VTE causes signiﬁcant YLD because of the non-fatal
consequences of DVT and PE. Despite treatment, about 10% to 20% of pa-
tients with DVT develop severe post-thrombotic syndrome, a chronic
disorder that decreases quality of life and reduces the capacity to walk
and to work [80,81]. In the most severe cases, patients with post-
thrombotic syndrome can develop venous ulcers, which are slow to
heal and costly for the healthcare system [80,81]. Heit and colleagues
reported an incidence of venous ulcers of 1.8 per 1,000 population per
year [82]. PE is associated with chronic thromboembolic pulmonary
hypertension in up to 4% of patients [83]. Patients with this disorder
have varying degrees of respiratory and cardiac impairment. Therefore,
the long-term consequences of VTE are associated with considerable
disability, and are likely to produce signiﬁcant YLD. Consequently, the
disease burden of VTE occurs through both YLL and YLD. More recently,
the long-termpsychological consequences of PE have been documented
to include emotional distress, worry and anxiety due to uncertainty
about whether or when a recurrence might occur, and in some cases,
symptoms characteristic of post-traumatic stress disorder [84].
Therefore, in addition to the physical burden, there is also an emotional
burden associated with VTE.
VTE may affect more people than those who suffer from it. First, cur-
rent prevention strategies must be applied to large numbers of patients
at risk.Most of these patients receive anticoagulant thromboprophylaxis,
which is associated with major bleeding in 0.2% to 1.1% of patients
[85–87]. Patients with thrombosis, particularly if they have a positive
family history, are often tested for hereditary or acquired thrombophilic
conditions. If abnormalities are found, this testing is sometimes extended
to family members, which may lead to medical interventions, and have
psychological consequences. The perceived risk of thrombosis affects
many more people than those actually afﬂicted by it.
VTEwasnot assessed as a cause of death at thedisaggregated level in
GBD 2010 [3,5,6]. GBD 2010 used three criteria for including causes of
death at the disaggregated level: potentially large burden, substantial
health policy interest, and the feasibility of measurement [5]. We be-
lieve that VTE meets all of these criteria. The feasibility of evaluating
VTE across the global regions is established by the results of the WHO
Patient Safety Program [72,74,75]. TheWHO is commended for including
VTE among the adverse outcomes assessed in the Patient Safety Program.
Future efforts of the GBD study should include evaluation of VTE as a
cause of death and the associated DALYs, both for hospital- associated
events, which account for up to 60% of all VTE [78], and also for events
that occur outside the hospital setting, such as unprovoked VTE.
Prevention is the key to reducing death and disability from VTE. This
includes thromboprophylaxis in patients at risk (primary prevention),
such as those undergoing surgery or those hospitalized with medical
illnesses [10–12], and prevention of recurrent thromboembolic events
in patients with established DVT or PE [88] (secondary prevention).
Effective primary prevention is available for most high risk patient
groups [10–12]. However, a global audit of utilization of primary
thromboprophylaxis documented widespread underuse in eligible pa-
tients [89]. There is evidence that a concerted effort by a health system
to include VTE risk assessment at the time of hospital admission and the
provision of appropriate primary thromboprophylaxis is effective for re-
ducing VTE-related death and readmission with nonfatal VTE [90,91].
The increased implementation of proven, evidence-based primary pre-
vention against VTE should be a global health priority. The safety and
simplicity of extended anticoagulant therapy has improved signiﬁcantlyin recent years [88], and this approach to secondary prevention has the
potential tomarkedly reduce the burden from recurrent venous throm-
boembolic events if appropriately implemented on a global scale. Future
research may further reﬁne our ability to optimize the beneﬁt-to-risk
proﬁle of anticoagulant treatment at the individual patient level, and
minimize the side-effects of prevention. Strengthening the global effort
to prevent VTE is consistent with the World Health Assembly’s goal of
signiﬁcantly reducing the global burden from non-communicable
diseases by 2025 [92].
In conclusion, this literature review found substantial evidence of a
major global disease burden from VTE. Although this burden has been
less extensively evaluated than the burden from arterial thrombosis,
which includes ischemic heart disease and ischemic stroke, the available
evidence indicates a major burden of disease across low, middle, and
high income countries. Because many of these events are potentially
preventable, more detailed data on the burden due to VTE should be ob-
tained to inform public health policy and resource allocation in health
systems, especially in regionswhere evidence is now limited or lacking,
and to evaluate whether the broader and improved implementation of
preventive measures will reduce the disease burden.
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